A French diagnostics company has just launched a point-of-care blood test that can measure a key heart attack marker in about 10 minutes instead of the 90 minutes a standard hospital laboratory typically needs. The device, unveiled on September 24, 2026, measures high-sensitivity cardiac troponin I directly from a drop of blood at the bedside, and a new 2026 meta-analysis in the Emergency Medicine Journal suggests this new generation of rapid troponin tests can match the accuracy of central laboratory testing. Here is what the news means, and what troponin results actually tell you about your heart.
A New 10-Minute Troponin Test Just Reached the Emergency Room
bioMerieux, a diagnostics company based in Marcy-l’Etoile, France, has launched SPINCHIP hs-cTnI, a compact platform designed to measure high-sensitivity cardiac troponin I in around 10 minutes from a single drop of blood, compared with roughly 90 minutes for many standard laboratory workflows. The company built the device after acquiring Norwegian firm SpinChip Diagnostics, and it has now obtained CE marking, the certification that allows a medical device to be sold across Europe. “With SPINCHIP, we bring our historic immunoassay know-how directly into emergency departments, as close as possible to the patient,” said bioMerieux CEO Pierre Boulud in the launch announcement.
The platform is aimed squarely at emergency departments, where doctors evaluating chest pain need a fast, reliable answer about whether a patient is having a heart attack.
Why the Speed of a Troponin Test Matters
Troponin is a protein released into the bloodstream when heart muscle cells are damaged, and measuring it is the cornerstone of diagnosing a heart attack, medically known as acute myocardial infarction. When someone arrives at an emergency department with chest pain, clinicians typically draw blood for troponin at least twice, an hour or more apart, to see whether the level is rising, falling, or staying flat.
The Bottleneck Has Always Been Turnaround Time
The chemistry behind a troponin test is not new. What has historically slowed things down is transporting a sample to a central laboratory, processing it, and returning a result, a cycle that can stretch to 60 or 90 minutes per draw. For an overcrowded emergency department, that delay adds up: patients wait longer for a diagnosis, beds stay occupied longer, and low-risk patients who could safely go home spend extra hours in an observation unit. A device that produces a lab-grade result at the bedside in minutes shortens every step of that chain at once.
What the Latest Research Says About Rapid Troponin Testing
According to PubMed, the clinical evidence on point-of-care troponin testing has shifted significantly in the past few years, and the distinction between older and newer devices matters. A 2025 systematic review and meta-analysis in Circulation Reports found that older-generation, non-high-sensitivity point-of-care troponin assays caught only about 47 percent of heart attacks on their own, even though they correctly ruled out around 90 percent of true negatives (DOI). In plain terms, an older-style rapid troponin test alone was not sensitive enough to safely rule out a heart attack.
Newer high-sensitivity point-of-care platforms tell a different story. A 2026 systematic review and meta-analysis in the Emergency Medicine Journal pooled data from eight studies and more than 9,300 patients across four high-sensitivity point-of-care platforms, including bioMerieux’s SPINCHIP, and found that structured testing protocols using two blood draws an hour or two apart achieved a pooled sensitivity of 98 percent and a negative predictive value of 99.9 percent for ruling out a heart attack, with results available in 8 to 17 minutes per draw (DOI). A separate 2026 multicenter study in the European Heart Journal: Acute Cardiovascular Care reported that a similar rapid protocol safely identified two-thirds of chest pain patients as low risk within two hours, with a negative predictive value of 99.9 percent (DOI).
What this means for patients: a single fast troponin reading is not meant to replace the standard two-draw protocol used to confirm or exclude a heart attack. Rather, the new generation of high-sensitivity point-of-care devices lets that same two-draw protocol run faster, so clinicians reach a confident answer sooner, not with a less rigorous test.
Lab Troponin Testing vs. Point-of-Care Troponin Testing
The table below summarizes the practical differences between the traditional laboratory pathway and the newer point-of-care approach now entering emergency departments.
| Feature | Central laboratory troponin | High-sensitivity point-of-care troponin |
|---|---|---|
| Typical turnaround | 45 to 90 minutes per draw | 8 to 17 minutes per draw |
| Sample location | Central hospital laboratory | Bedside, in the emergency department |
| Number of draws needed | Usually two, 1 to 2 hours apart | Usually two, 1 to 2 hours apart |
| Reported sensitivity for rule-out (2026 meta-analysis) | Reference standard | Approximately 98 percent |
| Where it currently helps most | All hospital settings | Busy emergency departments, and eventually pre-hospital and ambulance settings |
What This Means If You Go to the ER With Chest Pain
If you are evaluated for chest pain, understanding what a troponin result does and does not tell you can make the conversation with your care team easier to follow. AI DiagMe’s guide walks through how to interpret troponin test results in detail, including what counts as an elevated level and why context always matters more than a single number.
A rising troponin level is not automatically proof of a heart attack. Kidney disease, intense exercise, a fast heart rhythm, and severe infections can all raise troponin somewhat, which is why doctors evaluate the trend across two draws, the electrocardiogram, and symptoms together rather than relying on one isolated value. AI DiagMe also covers the complete cardiac markers panel for readers who want the fuller picture.
Seek emergency care immediately, rather than waiting to schedule routine bloodwork, if you experience chest pressure or pain, shortness of breath, pain spreading to the arm or jaw, cold sweats, or lightheadedness. A faster troponin result does not change that advice; it simply helps the medical team confirm or rule out a heart attack sooner once you are already being evaluated.
Glossary
- Troponin: a protein released by damaged heart muscle cells and measured in the blood to help diagnose a heart attack.
- High-sensitivity troponin (hs-cTn): a more precise version of the troponin test able to detect much smaller amounts of the protein than older assays.
- Point-of-care testing (POCT): laboratory testing performed at or near the patient, such as in an emergency department, instead of in a central laboratory.
- Acute myocardial infarction (AMI): the medical term for a heart attack, caused by a sudden blockage of blood flow to part of the heart muscle.
- Negative predictive value (NPV): the probability that a person with a negative test result truly does not have the condition being tested for.
- CE marking: certification indicating a medical device meets European Union health, safety, and environmental standards.
Frequently Asked Questions
Is a rapid troponin test as accurate as a standard laboratory troponin test?
Recent high-sensitivity point-of-care platforms have shown accuracy comparable to central laboratory assays in multiple 2025 and 2026 studies, according to PubMed, though real-world implementation studies are still ongoing to confirm these results across different hospital settings.
Does a single troponin reading rule out a heart attack?
No. Even with faster technology, doctors typically still compare two readings taken an hour or two apart, alongside your symptoms and an electrocardiogram, before ruling a heart attack in or out.
What does a high troponin level mean if I did not have a heart attack?
Troponin can rise for reasons other than a heart attack, including kidney disease, an irregular heart rhythm, intense physical exertion, or a severe infection. Your care team interprets the level alongside your full clinical picture.
Is this new test available in the United States?
As of its September 2026 launch, the device has CE marking and is being commercialized in Europe first. Point-of-care high-sensitivity troponin testing more broadly is already used in some emergency departments internationally, including in the United States.
Where can I learn more about interpreting my own troponin results?
AI DiagMe’s lab result explanations can help you understand a troponin value in the context of your overall blood work.
Sources
- bioMerieux: Launches SPINCHIP hs-cTnI, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I
- Pathology in Practice: bioMerieux introduces SPINCHIP POC platform with troponin assay
- MedlinePlus (NIH): Troponin Test
- American Heart Association: Diagnosing a Heart Attack
- Capodifoglio & De Iuliis, Emergency Medicine Journal (2026), via PubMed: Diagnostic accuracy of point-of-care high-sensitivity troponin algorithms
- Arai et al., Circulation Reports (2025), via PubMed: Diagnostic Accuracy of Initial Point-of-Care Troponin Tests
- Cullen et al., European Heart Journal: Acute Cardiovascular Care (2026), via PubMed: A new 0 and 2 hour risk assessment using point-of-care troponin
Related Reading on AI DiagMe
AI DiagMe also breaks down the related BNP cardiac blood marker, used mainly to evaluate heart failure rather than heart attacks, and explains the creatine kinase-MB cardiac marker, an older heart enzyme test that troponin has largely replaced. If you are managing a chronic heart condition, our guide also covers heart failure treatment options.
Understanding a single test result rarely tells the whole story. AI DiagMe’s AI-assisted platform helps you make sense of your lab results in context, drawing on a medically reviewed knowledge base. Understand your lab results with AI DiagMe.
